An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
Public ClinicalTrials.gov record NCT00528996. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.
Study identification
- NCT ID
- NCT00528996
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 2,080 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 6, 2007 (Actual)
- Primary completion
- May 5, 2009 (Actual)
- Completion
- May 5, 2009 (Actual)
- Last update posted
- Aug 24, 2021
2007 – 2009
United States locations
- U.S. sites
- 56
- U.S. states
- 25
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1205.14.061 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1205.14.054 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1205.14.042 Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| 1205.14.017 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 1205.14.022 Boehringer Ingelheim Investigational Site | Lakewood | California | — | — |
| 1205.14.046 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1205.14.008 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1205.14.047 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1205.14.037 Boehringer Ingelheim Investigational Site | Sepulveda | California | — | — |
| 1205.14.041 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1205.14.027 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 1205.14.034 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1205.14.050 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1205.14.013 Boehringer Ingelheim Investigational Site | Bay Pines | Florida | — | — |
| 1205.14.016 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1205.14.048 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1205.14.043 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 1205.14.040 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1205.14.007 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1205.14.053 Boehringer Ingelheim Investigational Site | Stockbridge | Georgia | — | — |
| 1205.14.014 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1205.14.035 Boehringer Ingelheim Investigational Site | Olathe | Kansas | — | — |
| 1205.14.057 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1205.14.052 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1205.14.036 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1205.14.019 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 1205.14.018 Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| 1205.14.032 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1205.14.033 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 1205.14.044 Boehringer Ingelheim Investigational Site | Brick | New Jersey | — | — |
| 1205.14.056 Boehringer Ingelheim Investigational Site | Cherry Hill | New Jersey | — | — |
| 1205.14.058 Boehringer Ingelheim Investigational Site | Summit | New Jersey | — | — |
| 1205.14.010 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1205.14.062 Boehringer Ingelheim Investigational Site | Larchmont | New York | — | — |
| 1205.14.028 Boehringer Ingelheim Investigational Site | Mineola | New York | — | — |
| 1205.14.030 Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| 1205.14.021 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1205.14.059 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1205.14.012 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1205.14.031 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1205.14.003 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1205.14.004 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1205.14.005 Boehringer Ingelheim Investigational Site | Johnston | Rhode Island | — | — |
| 1205.14.029 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1205.14.055 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1205.14.020 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1205.14.045 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1205.14.025 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1205.14.060 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1205.14.002 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1205.14.023 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1205.14.024 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1205.14.026 Boehringer Ingelheim Investigational Site | Roanoke | Virginia | — | — |
| 1205.14.009 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1205.14.039 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1205.14.001 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00528996, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00528996 live on ClinicalTrials.gov.